Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
Status:
Terminated
Trial end date:
2010-12-14
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of
ALXN6000 (samalizumab) in treating relapsing or refractory B-cell chronic lymphocytic
leukemia (B-CLL) or multiple myeloma (MM) and to study how samalizumab may help the immune
system fight tumors that express CD200.